NASDAQ:INBX

Inhibrx Competitors

$18.03
-2.95 (-14.06 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$17.91
Now: $18.03
$20.90
50-Day Range
$16.27
MA: $22.47
$29.75
52-Week Range
$15.20
Now: $18.03
$50.97
Volume128,524 shs
Average Volume147,164 shs
Market Capitalization$680.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Inhibrx (NASDAQ:INBX) Vs. VCEL, EDIT, SRNE, BCRX, RUBY, and BLUE

Should you be buying INBX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Inhibrx, including Vericel (VCEL), Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), BioCryst Pharmaceuticals (BCRX), Rubius Therapeutics (RUBY), and bluebird bio (BLUE).

Vericel (NASDAQ:VCEL) and Inhibrx (NASDAQ:INBX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Earnings and Valuation

This table compares Vericel and Inhibrx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$117.85 million22.93$-9,660,000.00$0.18325.67
InhibrxN/AN/AN/AN/AN/A

Inhibrx has lower revenue, but higher earnings than Vericel.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vericel and Inhibrx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vericel02602.75
Inhibrx00403.00

Vericel currently has a consensus target price of $49.00, suggesting a potential downside of 16.41%. Inhibrx has a consensus target price of $34.6667, suggesting a potential upside of 92.27%. Given Inhibrx's stronger consensus rating and higher possible upside, analysts plainly believe Inhibrx is more favorable than Vericel.

Insider and Institutional Ownership

93.1% of Vericel shares are owned by institutional investors. Comparatively, 36.6% of Inhibrx shares are owned by institutional investors. 4.3% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Vericel and Inhibrx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vericel0.12%0.13%0.10%
InhibrxN/AN/AN/A

Summary

Vericel beats Inhibrx on 7 of the 9 factors compared between the two stocks.

Inhibrx (NASDAQ:INBX) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Inhibrx and Editas Medicine's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InhibrxN/AN/AN/AN/AN/A
Editas Medicine$20.53 million113.76$-133,750,000.00($2.68)-12.94

Inhibrx has higher earnings, but lower revenue than Editas Medicine.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Inhibrx and Editas Medicine, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inhibrx00403.00
Editas Medicine44402.00

Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. Editas Medicine has a consensus price target of $47.3636, suggesting a potential upside of 36.61%. Given Inhibrx's stronger consensus rating and higher possible upside, research analysts clearly believe Inhibrx is more favorable than Editas Medicine.

Insider and Institutional Ownership

36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 87.5% of Editas Medicine shares are owned by institutional investors. 0.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Inhibrx and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InhibrxN/AN/AN/A
Editas Medicine-99.62%-26.74%-16.38%

Summary

Inhibrx beats Editas Medicine on 5 of the 8 factors compared between the two stocks.

Inhibrx (NASDAQ:INBX) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Inhibrx and Sorrento Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InhibrxN/AN/AN/AN/AN/A
Sorrento Therapeutics$31.43 million66.93$-292,070,000.00($2.12)-3.53

Inhibrx has higher earnings, but lower revenue than Sorrento Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Inhibrx and Sorrento Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inhibrx00403.00
Sorrento Therapeutics00403.00

Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. Sorrento Therapeutics has a consensus price target of $28.75, suggesting a potential upside of 283.85%. Given Sorrento Therapeutics' higher possible upside, analysts clearly believe Sorrento Therapeutics is more favorable than Inhibrx.

Insider and Institutional Ownership

36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Inhibrx and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InhibrxN/AN/AN/A
Sorrento Therapeutics-698.01%-314.06%-43.60%

Summary

Inhibrx beats Sorrento Therapeutics on 4 of the 7 factors compared between the two stocks.

Inhibrx (NASDAQ:INBX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Inhibrx and BioCryst Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InhibrxN/AN/AN/AN/AN/A
BioCryst Pharmaceuticals$48.83 million40.86$-108,900,000.00($0.94)-11.96

Inhibrx has higher earnings, but lower revenue than BioCryst Pharmaceuticals.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Inhibrx and BioCryst Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inhibrx00403.00
BioCryst Pharmaceuticals03802.73

Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. BioCryst Pharmaceuticals has a consensus price target of $12.3333, suggesting a potential upside of 9.73%. Given Inhibrx's stronger consensus rating and higher possible upside, research analysts clearly believe Inhibrx is more favorable than BioCryst Pharmaceuticals.

Insider and Institutional Ownership

36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Inhibrx and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InhibrxN/AN/AN/A
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%

Summary

Inhibrx beats BioCryst Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Inhibrx (NASDAQ:INBX) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Insider and Institutional Ownership

36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 93.7% of Rubius Therapeutics shares are owned by institutional investors. 58.4% of Rubius Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Inhibrx and Rubius Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InhibrxN/AN/AN/A
Rubius TherapeuticsN/A-77.33%-49.05%

Valuation & Earnings

This table compares Inhibrx and Rubius Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InhibrxN/AN/AN/AN/AN/A
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-11.68

Analyst Ratings

This is a breakdown of recent ratings and price targets for Inhibrx and Rubius Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inhibrx00403.00
Rubius Therapeutics03102.25

Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. Rubius Therapeutics has a consensus price target of $23.3333, suggesting a potential downside of 2.17%. Given Inhibrx's stronger consensus rating and higher possible upside, research analysts clearly believe Inhibrx is more favorable than Rubius Therapeutics.

Summary

Inhibrx beats Rubius Therapeutics on 5 of the 7 factors compared between the two stocks.

Inhibrx (NASDAQ:INBX) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

36.6% of Inhibrx shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 3.6% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Inhibrx and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InhibrxN/AN/AN/A
bluebird bio-256.84%-45.78%-35.14%

Earnings and Valuation

This table compares Inhibrx and bluebird bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InhibrxN/AN/AN/AN/AN/A
bluebird bio$44.67 million42.51$-789,610,000.00($14.31)-1.98

Inhibrx has higher earnings, but lower revenue than bluebird bio.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Inhibrx and bluebird bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inhibrx00403.00
bluebird bio012602.33

Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. bluebird bio has a consensus price target of $61.40, suggesting a potential upside of 112.16%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Inhibrx.

Summary

bluebird bio beats Inhibrx on 5 of the 9 factors compared between the two stocks.


Inhibrx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Vericel logo
VCEL
Vericel
1.1$58.62-1.1%$2.70 billion$117.85 million-5,862,000.00Increase in Short Interest
Editas Medicine logo
EDIT
Editas Medicine
1.6$34.67-18.2%$2.34 billion$20.53 million-19.93Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.49-0.7%$2.10 billion$31.43 million-5.13Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$24.30-1.0%$1.97 billionN/A-11.36Decrease in Short Interest
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.28-5.1%$1.90 billion$44.67 million-2.58
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.66-0.3%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$77.33-0.9%$1.72 billionN/A-52.25
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13
Immunovant logo
IMVT
Immunovant
1.8$15.42-3.0%$1.51 billionN/A-11.95Increase in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.51-3.9%$1.47 billion$35.23 million-13.92Increase in Short Interest
Replimune Group logo
REPL
Replimune Group
1.5$30.23-2.8%$1.45 billionN/A-17.08
AlloVir logo
ALVR
AlloVir
1.4$22.08-2.4%$1.44 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.84-4.5%$1.42 billion$7.80 million-17.61
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.55-1.1%$1.40 billionN/A0.00Increase in Short Interest
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$25.65-10.4%$1.21 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.77-0.4%$1.05 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.39-1.0%$1.05 billion$356.07 million7.05
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.22-7.0%$935.20 millionN/A0.00Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.86-2.5%$934.53 millionN/A-4.27Insider Selling
Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.01-6.7%$918.30 million$42.74 million-222.33Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.86-4.4%$900.98 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86-6.1%$866.47 million$250,000.00-6.98Analyst Upgrade
News Coverage
Gap Up
Passage Bio logo
PASG
Passage Bio
1.8$15.88-8.3%$854.84 millionN/A0.00Increase in Short Interest
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.40-0.5%$829.93 million$22.99 million-10.32
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.25-3.9%$809.32 million$69.89 million-4.12
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.93-2.2%$766.45 million$1.12 million-4.98Increase in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.02-5.3%$744.64 million$2.51 million-3.65
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.11-2.3%$686.71 million$14.75 million-2.62Increase in Short Interest
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.00-1.3%$648.22 million$5.78 million-9.39Insider Selling
Unusual Options Activity
Analyst Revision
Vaxart logo
VXRT
Vaxart
1.3$5.35-1.5%$630.05 million$9.86 million-9.07
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.08-1.6%$623.24 million$13.29 million-9.99
Athira Pharma logo
ATHA
Athira Pharma
2.1$16.59-0.8%$615.82 millionN/A0.00Analyst Downgrade
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.61-7.1%$586.59 millionN/A0.00Lockup Expiration
Gap Down
Compugen logo
CGEN
Compugen
1.4$8.57-3.9%$586.36 million$17.80 million-23.16Analyst Report
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.04-2.6%$538.67 millionN/A-2.45Increase in Short Interest
Agenus logo
AGEN
Agenus
1.6$2.62-1.5%$536.28 million$150.05 million-2.40
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.55-4.1%$531.02 millionN/A-1.25Gap Up
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.45-4.4%$529.86 millionN/A-5.89Gap Up
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.77-1.9%$501.14 million$22.24 million-4.36Increase in Short Interest
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.12-7.0%$454.86 millionN/A-8.00Increase in Short Interest
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.